ImmuPharma (LON:IMM) Stock Price Down 11.6% - Should You Sell?

Key Points

• ImmuPharma's stock price dropped by 11.6%, closing at GBX 15.55 ($0.21) after trading as low as GBX 14.10 ($0.19).
• The company reported a substantial decrease in trading volume, with 28.6 million shares traded, a 241% increase from its average volume.
• ImmuPharma has a market cap of £77.71 million and is expected to post a negative earnings per share of -339.0000022 for the current fiscal year.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) fell 11.6% during trading on Tuesday . The company traded as low as GBX 14.10 ($0.19) and last traded at GBX 15.55 ($0.21). 28,608,859 shares changed hands during mid-day trading, an increase of 241% from the average session volume of 8,383,843 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Stock Down 11.6%

The stock has a market cap of £77.71 million, a price-to-earnings ratio of -1,747.19 and a beta of 1.53. The business's 50 day simple moving average is GBX 3.43 and its 200 day simple moving average is GBX 3.01.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.